In the future, it is necessary to establish humanized models that integrate diabetes comorbidities (insulin resistance, lipid metabolism disorders), conduct phase III clinical trials lasting ≥1 year with renal histopathological endpoints, and directly compare the efficacy of sGC activators and stimulators at different stages of DKD. This evidence concerns the gene SGCB and diabetes mellitus.